Prediction Case File
YouTubeTracking Live

2 Growth Stocks I will NEVER Sell!

2 extracted signals · 0 resolved · 2 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
06 Sept 2026, 13:18 UTC
Recorded by Tahlil Plus
06 Sept 2026, 13:23 UTC
Video preview for 2 Growth Stocks I will NEVER Sell!
Source overview

AI-generated source summary

The analysis covers two stocks: HOOD and MAMA. HOOD is trading at $122.11, with a target price of $82.5, suggesting a bearish prediction. The fail bound for this bearish outlook is set at $130.00. The company's recent financial performance and diversification efforts are highlighted as positive indicators, but the valuation is considered expensive at 40x earnings. MAMA is trading at $15.16, with a target price of $12.00, indicating a bullish prediction. The fail bound for this bullish outlook is set at $16.00. The company's strong revenue growth, high net income margin, and strategic acquisitions are presented as positive factors, despite recent price declines. The analysis suggests that MAMA's current valuation is undervalued, offering a good buying opportunity.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
2
Extracted from this source
Open
2
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    2 eligible signals linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    2 signals remain active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.2
Tracked signals
329
Historical success
33.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail